Immune cell therapy with a PD-1 blocker for young people with medulloblastoma that came back
Original title: Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in a small number of people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether immune cell treatment plus a PD-1 blocker is safe for children and young adults whose medulloblastoma has come back or is growing.
Who this trial is for. This trial is for children and young adults who may have medulloblastoma that has come back or is getting worse. It is a small pilot study of adoptive cell therapy, which uses immune cells, given with a drug called a PD-1 blocker.
Where it stands. The trial has not reported results. It is looking at whether this treatment can be given and whether it is safe. That answer is not in yet.
What this means, and what it doesn't
What it could mean: This is one of the things being tried for medulloblastoma that comes back. If your child or the person you care for fits this picture, you could ask the care team about it. The care team can tell you if it is worth looking into.
What it doesn't mean: It does not mean this treatment works. A trial is a test, not a proven treatment. Being in one is not a guarantee that it will help. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 7, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.